Program
calderasib
Also written as “Calderasib”, “MK-1084” and “[14C]Calderasib”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Neoplasms · Colonic Neoplasms · Renal Insufficiency, led by Merck.
Furthest: phase 3, since Mar 28, 202412 company-led studies, 8 open or runningNext primary completion: Jan 24, 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 128 open or running | phase 3since Mar 28, 2024 | Oct 1, 2021 | Jan 24, 2028phase 3 · NCT06345729 |
- Named in Merck’s own pipeline as
calderasib (MK-1084)
, phase 3, as of Nov 2, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 1, 2021First study: phase 1 study in Advanced Solid TumorsFirst studyNCT05067283 · 830 planned · United States, Argentina, Australia and more
- Mar 28, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06345729 · 348 planned · United States, Argentina, Australia and more
- Sep 26, 2024Phase 1 study in HealthyNCT06619314 · 56 enrolled · United States
- Nov 12, 2024Phase 1 study in HealthyNCT06687759 · 8 enrolled · United States
- Feb 3, 2025Phase 1 study in Renal InsufficiencyNCT06814119 · 34 enrolled · United States
- May 21, 2025Phase 3 study in Colonic NeoplasmsNCT06997497 · 477 planned · United States, Argentina, Australia and more
- Sep 16, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07190248 · 675 planned · United States, Argentina, Australia and more
- Sep 30, 2025Phase 2 study in NeoplasmsNCT07209111 · 150 planned · United States, Australia, Canada and more
- Oct 20, 2025Phase 1 study in HealthyNCT07219550 · 32 enrolled · United States
- Nov 20, 2025Phase 2 study in NeoplasmsNCT07252739 · 140 planned · United States, Chile, China and more
- Feb 19, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07431827 · 400 planned · Argentina, Australia, Brazil and more
- Apr 21, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07554339 · 310 planned · United States, Argentina, Australia and more
Ahead
- Jan 24, 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06345729
- Mar 28, 2029Primary completion: phase 3 study in Colonic NeoplasmsNCT06997497
- Nov 15, 2029Primary completion: phase 2 study in NeoplasmsNCT07252739
- Dec 7, 2029Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07190248
TargetBeta
“An orally available inhibitor of the oncogenic KRAS substitution mutation G12C, with potential antineoplastic activity. Upon oral administration, calderasib selectively targets the KRAS G12C mutant and inhibits KRAS G12C-mediated signaling. This may halt proliferation and metastasis in susceptibl…”NCIt, read by Claude
“An orally available inhibitor of the oncogenic KRAS substitution mutation G12C, ”NCIt, by rule
Other programs on KRAS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sotorasibrule | Amgen | phase 3 | 28 |
| adagrasibrule | Bristol-Myers Squibb | phase 3 | 16 |
| olomorasib | Eli Lilly | phase 3 | 16 |
| divarasib | Hoffmann-La Roche | phase 3 | 13 |
| KRAS G12D Inhibitor VS-7375rule | Genfleet Therapeutics (Shanghai) | phase 3 | 12 |
| glecirasibrule | Allist Pharmaceuticals | phase 3 | 12 |
| daraxonrasibrule | Revolution Medicines | phase 3 | 10 |
| garsorasibrule | InventisBio | phase 3 | 8 |
| KRAS G12D Inhibitor HRS-4642 | Jiangsu HengRui Medicine | phase 3 | 7 |
| zoldonrasibrule | Revolution Medicines | phase 3 | 6 |
| HRS-7058 | Jiangsu HengRui Medicine | phase 3 | 6 |
| opnurasibrule | Novartis | phase 3 | 5 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07554339Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Dec 15, 2032 | 310 |
| NCT07431827Carcinoma, Non-Small-Cell Lung · Argentina, Australia, Brazil and more | 3 | Recruiting | Oct 26, 2039 | 400 |
| NCT07252739Neoplasms · United States, Chile, China and more | 2 | Recruiting | Nov 15, 2029 | 140 |
| NCT07219550Healthy · United States | 1 | Completed | Jul 15, 2026 | 32 |
| NCT07209111Neoplasms · United States, Australia, Canada and more | 2 | Recruiting | Apr 9, 2032 | 150 |
| NCT07190248Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Dec 7, 2029 | 675 |
| NCT06997497Colonic Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Mar 28, 2029 | 477 |
| NCT06814119Renal Insufficiency · United States | 1 | Completed | Jan 23, 2026 | 34 |
| NCT06687759Healthy · United States | 1 | Completed | Aug 7, 2024 | 8 |
| NCT06619314Healthy · United States | 1 | Completed | Nov 25, 2023 | 56 |
| NCT06345729Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Jan 24, 2028 | 348 |
| NCT05067283Advanced Solid Tumors · United States, Argentina, Australia and more | 1 | Recruiting | Feb 25, 2030 | 830 |
How it is read
Names in the registry
- “Calderasib”, 10 entries
- “MK-1084”, 1 entry
- “[14C]Calderasib”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Neoplasms, 2 studies
- Colonic Neoplasms, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.